https://www.frontiersin.org/journals/drug-discovery/articles/10.3389/fddsv.2022.962988/full
created by Much-Pomegranate-822 on 01/01/2025 at 23:32 UTC
30 upvotes, 3 top-level comments (showing 3)
Comment by AutoModerator at 01/01/2025 at 23:32 UTC
1 upvotes, 0 direct replies
Keep in mind this is a *science* sub. Cite your sources appropriately (No news sources, no Twitter, no Youtube). No politics/economics/low effort comments (jokes, ELI5, etc.)/anecdotal discussion (personal stories/info). Please read our full ruleset[1] carefully before commenting/posting.
1: https://www.reddit.com/r/COVID19/about/rules/
2: /message/compose/?to=/r/COVID19
Comment by Opcn at 01/01/2025 at 23:51 UTC
37 upvotes, 1 direct replies
This is a case series of five patients with no controls from 2.5 years ago with zero total citations. Doesn't seem like a lot to go on, and reducing the oxygen requirement is the normal course of treatment for a patient that is improving. This is very poor quality evidence and really shouldn't be the basis for any decision making. Even on a home scale the damage from incorporating more superstitious thinking in an individual's approach would outweigh the potential benefits.
Pepto is still great for an upset stomach though. Use it for that, not for covid. Not based on this case series at least.
Comment by AcornAl at 02/01/2025 at 20:22 UTC
12 upvotes, 0 direct replies
Can I ask why you are posting old studies to multiple subs about a drug candidate that has never had a single clinical trial? It's just one of a couple dozen candidates[1] that could be used to inhibit the SARS-CoV-2 protease similar to nirmatrelvir + ritonavir.
1: https://pubs.acs.org/doi/full/10.1021/acsomega.4c03023
While this particular drug has been shown to have an antiviral effect, it has limited bioavailability[2] that will probably mean that it will not be a viable medication in it's current form.